v3.26.1
Segments - Schedule of Segment Reporting Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Segment loss $ 21,772 $ 58,935
Reconciliation of segment loss    
Interest and other (income) expense, net (1,732) (3,568)
Interest expense 0 799
Net loss 20,040 56,166
Reportable Segment    
Operating expenses:    
Program expense including clinical trial and third party contracting costs 5,585 1,436
Bexotegrast - clinical trial and third party contracting costs (777) 21,589
Employee-related expenses - research and development (excluding stock-based compensation) 3,537 10,486
General and administrative costs (excluding stock-based compensation) 5,661 10,289
Other segment items 7,766 15,135
Segment loss 21,772 58,935
Reconciliation of segment loss    
Interest and other (income) expense, net (1,732) (3,568)
Interest expense 0 799
Net loss $ 20,040 $ 56,166